Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 3,000 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. This represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Stock Down 0.3%

Shares of NASDAQ:CELC traded down $0.30 on Thursday, hitting $112.63. 501,390 shares of the company traded hands, compared to its average volume of 725,079. The stock has a 50 day simple moving average of $109.81 and a 200-day simple moving average of $92.12. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. The company has a market cap of $5.44 billion, a PE ratio of -29.72 and a beta of 0.41. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. As a group, research analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CELC. Stifel Nicolaus upped their target price on shares of Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $122.00 price objective on shares of Celcuity in a research report on Thursday, March 26th. Wall Street Zen upgraded Celcuity from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Wells Fargo & Company started coverage on Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Celcuity currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.88.

Institutional Trading of Celcuity

A number of institutional investors have recently made changes to their positions in CELC. NEA Management Company LLC grew its stake in shares of Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the period. Avoro Capital Advisors LLC bought a new position in Celcuity during the fourth quarter valued at approximately $310,302,000. Soleus Capital Management L.P. boosted its holdings in Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after purchasing an additional 437,696 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Celcuity by 10.7% in the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after purchasing an additional 220,386 shares during the last quarter. Finally, State Street Corp grew its position in Celcuity by 126.6% in the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after purchasing an additional 914,887 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.